title: Influence of tegaserod on proximal gastric tone and on the perception of gastric distention in functional dyspepsia.
abstract: BACKGROUND
  Abnormalities in gastric sensorimotor function (hypersensitivity to distention and impaired meal accommodation) have been implicated in the pathophysiology of functional dyspepsia (FD). To study the effect of the 5-HT(4) agonist tegaserod on sensitivity to gastric distention and gastric accommodation in FD.
  
  
  METHODS
  Thirty FD patients (7 males, mean age 42 ± 2 years) underwent a gastric barostat study on two separate occasions, 2 weeks apart, after 5 days of pretreatment with placebo or tegaserod 6 mg b.i.d. in a double-blind randomized order. After introduction of the barostat bag, graded isobaric distentions (2 mmHg increments/2 min) were performed to determine gastric compliance and sensitivity to distention. Subsequently, the pressure level was set at intra-abdominal pressure [minimal distending pressure (MDP)] + 2 mmHg for 90 min, with administration of a liquid meal (200 mL; 300 kcal) after 30 min.
  
  
  RESULTS
  Tegaserod had no influence on MDP (7.9 ± 0.4 vs 7.4 ± 0.4 mmHg) or fasting gastric compliance (44 ± 10 vs 61 ± 6 mL mmHg(-1)) and on fasting thresholds for first perception (3.6 ± 0.4 vs 4.2 ± 0.2 mmHg above MDP) or discomfort (9.9 ± 0.7 vs 10.5 ± 0.5 mmHg above MDP). Tegaserod did not alter intra-balloon volumes before and after the meal [respectively 146 ± 14 vs 120 ± 11 and 297 ± 28 vs 283 ± 29 mL, not significant (NS)], or the amplitude of the meal-induced gastric relaxation (151 ± 23 vs 162 ± 23 mL, NS). In the subgroup with normal gastric emptying (n = 22), tegaserod significantly enhanced meal-induced accommodation (126 ± 23 vs 175 ± 29 mL, ANOVA P < 0.001).
  
  
  CONCLUSIONS
  Tegaserod does not alter gastric sensorimotor function in FD patients as a group. In the subgroup with normal gastric emptying, tegaserod 6 mg b.i.d enhanced gastric accommodation.
authors.affiliation: Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium. jan.tack@med.kuleuven.ac.be
authors.forename: J
authors.initials: J
authors.lastname: Tack
authors.forename: P
authors.initials: P
authors.lastname: Janssen
authors.forename: R
authors.initials: R
authors.lastname: Bisschops
authors.forename: R
authors.initials: R
authors.lastname: Vos
authors.forename: T
authors.initials: T
authors.lastname: Phillips
authors.forename: G
authors.initials: G
authors.lastname: Tougas
mesh_terms: D000328:Adult; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004415:Dyspepsia / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005746:Gastric Emptying / Q000187:drug effects / Q000502:physiology; D005767:Gastrointestinal Diseases / Q000188:drug therapy / Q000503:physiopathology; D005769:Gastrointestinal Motility / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D007211:Indoles / Q000494:pharmacology* / Q000627:therapeutic use*; D008297:Male; D019518:Postprandial Period / Q000502:physiology; D017366:Serotonin Receptor Agonists / Q000494:pharmacology / Q000627:therapeutic use; D013270:Stomach / Q000187:drug effects* / Q000503:physiopathology; D016896:Treatment Outcome
chemical_list: D007211:Indoles; D017366:Serotonin Receptor Agonists; C105050:tegaserod